Zynteglo Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The zynteglo market research report is one of a series of new reports that provides zynteglo market statistics, including the zynteglo industry global market size, regional shares, competitors with the zynteglo market share, detailed zynteglo market segments, market trends, and opportunities, and any further data you may need to thrive in the zynteglo industry. This zynteglo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the rising incidence of thalassemia, the rise in healthcare infrastructure, the growing patient population for rare diseases, the growing focus on long-term treatment solutions, and the rising acceptance of costly treatments. Major trends in the forecast period include advancements in genetic editing technology, developing advanced treatments, integration of patient data to personalize treatments, innovation in clinical trials, and integration of cutting-edge gene-editing technologies.

The rising incidence of thalassemia is expected to significantly drive the growth of the zynteglo market. Thalassemia is a group of inherited blood disorders in which the body produces insufficient hemoglobin, leading to anemia. Factors such as high carrier rates in certain populations, genetic inheritance through consanguineous marriages, increased migration, limited awareness and screening, and better diagnosis and survival rates are contributing to the rising incidence of thalassemia. Zynteglo addresses this issue by offering a one-time gene therapy that enables patients to produce healthy hemoglobin, potentially eliminating the need for regular blood transfusions. For instance, in November 2024, the American Society of Hematology reported that in 2023, the prevalence of beta-thalassemia was approximately 3,665 cases, with a rate of 1.07 per 100,000 individuals. As such, the rising incidence of thalassemia is fueling the growth of the zynteglo market.

The growth of healthcare infrastructure is also expected to drive the expansion of the zynteglo market. Healthcare infrastructure encompasses physical facilities, organizational structures, equipment, personnel, and systems needed to deliver effective healthcare services. This rise in infrastructure can be attributed to factors such as population growth, advancements in medical technology, government investments, the increasing burden of chronic diseases, urbanization, medical tourism, and the aging population. Enhanced healthcare infrastructure supports the delivery of advanced treatments such as Zynteglo by improving diagnosis, logistics, and patient care. For example, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, a slight increase of 0.591% from the previous year’s total of 6,093 hospitals. This growth in healthcare infrastructure is further contributing to the growth of the zynteglo market.

One of the key trends in the zynteglo market is the development of innovative therapies, such as gene therapies, which offer long-term solutions for genetic disorders. Gene therapies involve altering the genes within a patient's cells to treat or prevent diseases by correcting defective genes or introducing new genetic material. A significant example is in August 2022, when Bluebird Bio Inc., a U.S.-based biotechnology company, received FDA approval for Zynteglo (betibeglogene autotemcel), a revolutionary one-time gene therapy designed to treat beta-thalassemia, a genetic blood disorder. Zynteglo became the first ex-vivo lentiviral vector gene therapy approved by the FDA for beta-thalassemia treatment. The therapy works by modifying a patient's stem cells to produce functional hemoglobin, potentially eliminating the need for regular red blood cell transfusions and iron chelation therapy.

The key company operating in the zynteglo market is Bluebird bio Inc.

North America was the largest region in the zynteglo market in 2024. The regions covered in zynteglo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zynteglo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Zynteglo is a gene therapy used to treat beta-thalassemia, a genetic blood disorder. The therapy involves modifying a patient's stem cells to produce functional hemoglobin, addressing the root cause of the disease. The treatment aims to reduce or eliminate the need for blood transfusions in patients with transfusion-dependent beta-thalassemia.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for zynteglo include beta-thalassemia and sickle cell disease. Beta-thalassemia is a genetic blood disorder where insufficient beta-globin is produced, leading to anemia and requiring medical interventions such as blood transfusions in severe cases. Zynteglo is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and serves a range of end users, including adults, pediatrics, and geriatric patients.

The zynteglo market consists of sales of autologous gene therapy, one-time curative therapy and cell therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.